Sygnature Discovery

JUNE 17, 2024

From hit finding and target engagement studies, to the characterisation of kinetic properties for late-stage candidate molecules, we believe that a biophysical approach complements other assays to deliver a fuller picture of binding behaviour to produce more effective therapeutics.

Biophysical Assays 52

Biophysical Assays Screening Hits Assay Development Fragment Screening 52

Drug Target Review

NOVEMBER 1, 2023

So that is a wide range of techniques to look at the protein-ligand interactions, all with the aim to guide the optimisation of our first screening hits to potent inhibitors that hopefully are cell-active at some point.

Fragment Screening 96

Fragment Screening Biochemical Assays Small Molecule Biophysical Assays 96

Practical Cheminformatics

AUGUST 3, 2023

Most pharmaceutical compounds tend to have solubilities somewhere between 1 and 500 µM. It is quite a bit more potent than the values one finds with screening hits, which typically have IC50s in the single to double-digit µM range. Many have suggested that pharmaceutical companies should open more of their data to the community.

Drugs 84

Drugs Biochemical Assays Metabolic Stability Screening Hits 84

Molecular Design

OCTOBER 14, 2018

The distinction between Type 1 and and Type 2 behaviors is an important and useful one to make from the perspective of drug discovery scientists who are making decisions as to which screening hits to take forward.

Screening Hits 52

Screening Hits FDA Approval Drugs FDA 52